Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 5, 2012 - Issue 5
Submit an article Journal homepage
113
Views
1
CrossRef citations to date
0
Altmetric
Drug Profile

Pegloticase and the patient with treatment-failure gout

Amish J Dave Department of Medicine, Stanford University Medical Center, Stanford, CA 94305, USA. [email protected]
,
Victoria M Kelly Department of Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
&
Eswar Krishnan Department of Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
Pages 501-508 | Published online: 10 Jan 2014

References

  • Wortmann RL, Kelley WN. Gout and hyperuricemia. In: Kelly’s Textbook of Rheumatology (7th Edition). Harris ED Jr, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, Sledge CB (Eds). WB Saunders, MO, USA, 1402–1429 (2005).
  • Anderson A, Singh JA. Pegloticase for chronic gout. Cochrane Database Syst. Rev. 3, CD008335 (2010).
  • Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 63(10), 3136–3141 (2011).
  • Terkeltaub RA. Clinical practice. Gout. N. Engl. J. Med. 349(17), 1647–1655 (2003).
  • Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J. Rheumatol. 29(11), 2403–2406 (2002).
  • Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr. Opin. Rheumatol. 17(3), 341–345 (2005).
  • Krishnan E. Gout: epidemiology and risk factors. In: Gout and Other Crystal Arthropathies. Terkeltaub R (Ed.). Saunders, PA, USA, 72–84 (2012).
  • Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res. Ther. 8(Suppl. 1), S2 (2006).
  • So A. Developments in the scientific and clinical understanding of gout. Arthritis Res. Ther. 10(5), 221 (2008).
  • Eggebeen AT. Gout: an update. Am. Fam. Physician 76(6), 801–808 (2007).
  • Stevenson M, Pandor A. Febuxostat for the management of hyperuricemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics 29(2), 133–140 (2011).
  • Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann. Rheum. Dis. 57(9), 545–549 (1998).
  • Baraf HS, Matsumoto AK, Maroli AN, Waltrip RW 2nd. Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum. 58(11), 3632–3634 (2008).
  • Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am. J. Med. 25(7), 679.e1–687.e1 (2012).
  • Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am. J. Med. 76(1), 47–56 (1984).
  • Becker MA, Schumacher HR, Wortmann RL et al. A study comparing safety and efficiency of oral febuxostat and allopurinol in subjects with hyperuricemia and gout. N. Engl. J. Med. 353, 2450 (2005).
  • Li-Yu J, Clayburne G, Sieck M et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J. Rheumatol. 28(3), 577–580 (2001).
  • Reinders MK, Jansen TL. New advances in the treatment of gout: review of pegloticase. Ther. Clin. Risk Manag. 6, 543–550 (2010).
  • Kelly VM, Krishnan E. Febuxostat for the treatment of hyperuricemia in patients with gout. Int. J. Clin. Rheumatol. 6(5), 485–493 (2011).
  • Rozenberg S, Roche B, Dorent R, Koeger AC, Borget C, Wrona N et al. Urate-oxidase for the treatment of tophaceous gout in heart transplant patients: a report of three cases. Rev. Rheum. Eng. Ed. 62, 392–394 (1995).
  • Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol. Dial. Transplant. 20(2), 431–433 (2005).
  • Moolenburgh JD, Reinders MK, Jansen TL. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin. Rheumatol. 25(5), 749–752 (2006).
  • Richette P, Brière C, Hoenen-Clavert V, Loeuille D, Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J. Rheumatol. 34(10), 2093–2098 (2007).
  • Sundy JS, Becker MA, Baraf HS et al.; Pegloticase Phase 2 Study Investigators. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a Phase II randomized study. Arthritis Rheum. 58(9), 2882–2891 (2008).
  • Sundy JS, Ganson NJ, Kelly SJ et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 56(3), 1021–1028 (2007).
  • Chohan S, Becker MA. Update on emerging urate-lowering therapies. Curr. Opin. Rheumatol. 21(2), 143–149 (2009).
  • Sundy JS, Baraf HS, Yood RA et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306(7), 711–720 (2011).
  • Krystexxa®, package insert. Savient Pharmaceuticals, Inc., NJ, USA.
  • Reinders MK, Jansen TL. Management of hyperuricemia in gout: focus on febuxostat. Clin. Interv. Aging 5, 7–18 (2010).
  • Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 20(3), 895–900 (1977).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.